V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age

The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes of S. pneumoniae.

Inclusion Criteria:

• In good health
• 12 to 15 months of age
• Negative clinical history to measles, mumps, rubella, varicella and/or zoster
• Received only the 3-dose primary series of a pneumococcal conjugate vaccine with at least 2 months prior to the receipt of any of the study vaccines
• Signed consent

Exclusion Criteria:

• Previous administration of any measles, mumps, rubella, or varicella vaccine either alone or in any combination
• Any condition resulting in depressed immunity
• Any allergy to any vaccine component as stated in the package circulars
• Exposure to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination
• History of seizure disorder
• Receipt of an inactivated vaccine within 14 days prior to enrollment or live vaccine within 30 days
• Recent febrile illness